The clinical and health economic burden of respiratory syncytial virus disease among children under 2 years of age in a defined geographical area

Archives of Disease in Childhood

Volumn 88, Issue 12, 2003, Pages 1065-1069

  Deshpande, S A ^a   Northern, V ^b  

^a ROYAL SHREWSBURY HOSPITAL   (United Kingdom)

^b Shropshire's Comm Mental Hlth S   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ASSISTED VENTILATION; BRONCHIOLITIS; CHRONIC LUNG DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; ECONOMIC ASPECT; FEMALE; GEOGRAPHIC DISTRIBUTION; GESTATIONAL AGE; HIGH RISK POPULATION; HOSPITAL COST; HOSPITALIZATION; HUMAN; IMMUNOPROPHYLAXIS; INFANT; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEWBORN PERIOD; OXYGEN THERAPY; PRESCHOOL CHILD; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT DISEASE;

BRONCHIOLITIS, VIRAL; COSTS AND COST ANALYSIS; ENGLAND; FEMALE; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE, DISEASES; INTENSIVE CARE, NEONATAL; MALE; OXYGEN; PROGNOSIS; RESPIRATION, ARTIFICIAL; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RISK FACTORS; RURAL HEALTH;

EID: 0347320558     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.88.12.1065     Document Type: Article

References (25)

1. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001;344:1917-28.
2. The IMpact-RSV Study Group. Palivizumab, a humanised respiratory syncytial virus monoclonal antibody, reduces hospitalisation from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531-7.
3. Joffe S, Ray GT, Escobar GJ, et al. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 1999;104:419-27.
4. Moler FW. RSV immune globulin prophylaxis: is an ounce of prevention worth a pound of cure? Pediatrics 1999;104:559-60.
5. Joffe S, Escobar GJ, Black SB, et al. Rehospitalization for respiratory syncytial virus among premature infants. J Pediatr 1999;104:894-9.
6. Thomas M, Bedford-Russell A, Sharland M. Hospitalisation for RSV infection in ex-preterm infants - implications for use of RSV immune globulin. Arch Dis Child 2000;83:122-7.
7. Clark SJ, Beresford MW, Subhedar NV, et al. Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort. Arch Dis Child 2000;83:313-16.
8. Martin AJ, Gardner PS, McQuillin J. Epidemiology of respiratory viral infection among paediatric inpatients over a six-year period in north-east England. Lancet 1978;ii:1035-8.
9. Anon. Report to the Medical Research Council subcommittee on respiratory syncytial virus vaccines. Respiratory syncytial virus infection: admissions to hospital in industrial, urban, and rural areas. BMJ 1978;ii:796-8.
10. Simoes EA, Sondheimer HM, Top FHJ, et al. Respiratory syncytial virus immnue globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. J Pediatr 1998;133:492-9.
11. World Health Organisation. International statistical classification of diseases and related health problems, 10th revision. Geneva: WHO, 1992.
12. Information and Statistics Division. Births in Scotland. Edinburgh: Common Services Agency for NHS Scotland. Available at http:// www.show.scot.nhs.uk/isd/sexual_health/births_in_scottishhosps/Table 10.htm (accessed 11 September 2002).
13. Wren C, Richmond S, Donaldson L. Temporal variability in birth prevalence of cardiiovascular malformations. Heart 2000;83:41-9.
14. Manktelow BN, S DE, Annamali S, et al. Factors affecting the incidence of chronic lung disease of prematurity in 1987, 1992, and 1997. Arch Dis Child Fetal Neonatal Ed 2001;85:F33-5.
15. Greenough A, Alexander J, Burgess S, et al. Home oxygen status and rehospitalisation and primary care requirements of infants with chronic lung disease. Arch Dis Child 2002;86:40-3.
16. Lemons JA, Bouer CR, Oh W, et al. Very low birth weight infants of the National Institute of Child Health and Human Development Neonatal Research Network, January 1995 through December 1996. Pediatrics 2001;107:el. Available at: http://www.pediatrics.org/cgi/content/full/ 107/1/el.
17. Shay DK, Holmon RC, Newmon RD, et al. Bronchiolitis-associated hospitalizations among US Children, 1980-96. JAMA 1999;282:1440-6.
18. Sims DG, Downhom MA, McQuillin J, et al. Respiratory syncytiol virus infection in north-east England. BMJ 1976;2:1095-8.
19. Spencer N, Logan S, Scholey S, et al. Deprivation and bronchiolitis. Arch Dis Child 1996;74:50-2.
20. Nachman SA, Navaie-Waliser M, Qureshi MZ. Rehospitalisation with respiratory syncytial virus after neonatal intensive care unit discharge: a 3-year follow up. Pediatrics 1997;100:e8. Available at: http:// www.pediatrics.org/cgi/content/full/100/6/e8.
21. Department of Health. Hospital in-patient data based on hospital episode statistics (HES). London: DoH, 2001. Available at: http://www.doh.gov.uk/ hes/standard_data/available_tables/primary_diagnosis/tb00398a.pdf (accessed 10 April 2001).
22. Office for National Statistics. Mid-1998 population estimates. Population estimates mid-1998 and mid-1999 based. London: Office for National Statistics, 2000.
23. Navas L, Wang E, de Carvalho V, et al. Improved outcome of respiratory syncytial virus infection in a high-risk hospitalised population of Canadian children. J Pediatr 1992;121:348-54.
24. Briggs A. Economic evaluation and clinical trials: size matters. BMJ 2000;321:1362-3.
25. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palvizumab and update on the use of RSV. Pediatrics 1998;102:1211-16.